A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.

Autor: Gambaro K; Canadian National Centres of Excellence-Exactis Innovations, Montreal, QC H3T 1Y6, Canada.; Consortium de Recherche en Oncologie Clinique du Québec (Q-CROC), Quebec, QC G1V 3X8, Canada.; Segal Cancer Centre-Jewish General Hospital, Montreal, QC H3T 1E2, Canada., Marques M; Canadian National Centres of Excellence-Exactis Innovations, Montreal, QC H3T 1Y6, Canada.; Segal Cancer Centre-Jewish General Hospital, Montreal, QC H3T 1E2, Canada., McNamara S; Canadian National Centres of Excellence-Exactis Innovations, Montreal, QC H3T 1Y6, Canada.; Consortium de Recherche en Oncologie Clinique du Québec (Q-CROC), Quebec, QC G1V 3X8, Canada., Couetoux du Tertre M; Canadian National Centres of Excellence-Exactis Innovations, Montreal, QC H3T 1Y6, Canada.; Consortium de Recherche en Oncologie Clinique du Québec (Q-CROC), Quebec, QC G1V 3X8, Canada., Hoffert C; Canadian National Centres of Excellence-Exactis Innovations, Montreal, QC H3T 1Y6, Canada.; Consortium de Recherche en Oncologie Clinique du Québec (Q-CROC), Quebec, QC G1V 3X8, Canada.; Segal Cancer Centre-Jewish General Hospital, Montreal, QC H3T 1E2, Canada., Srivastava A; Canadian National Centres of Excellence-Exactis Innovations, Montreal, QC H3T 1Y6, Canada.; Consortium de Recherche en Oncologie Clinique du Québec (Q-CROC), Quebec, QC G1V 3X8, Canada.; Segal Cancer Centre-Jewish General Hospital, Montreal, QC H3T 1E2, Canada., Schab A; Canadian National Centres of Excellence-Exactis Innovations, Montreal, QC H3T 1Y6, Canada.; Consortium de Recherche en Oncologie Clinique du Québec (Q-CROC), Quebec, QC G1V 3X8, Canada., Alcindor T; McGill University Health Centre, Montreal, QC H4A 3J1, Canada., Langleben A; St. Mary's Hospital, Montreal, QC H3T 0A2, Canada., Sideris L; Hôpital Maisonneuve Rosemont, Montreal, QC H1T 2M4, Canada., Abdelsalam M; The Moncton Hospital, Moncton, NB E1C 6Z8, Canada., Tehfe M; Hematology-Oncology, Oncology Center-Centre Hospitalier de l'Université de Montreal, Montreal, QC H2X 0C1, Canada., Couture F; Hôtel-Dieu de Québec, Quebec, QC G1R 2J6, Canada., Batist G; Segal Cancer Centre-Jewish General Hospital, Montreal, QC H3T 1E2, Canada., Kavan P; Segal Cancer Centre-Jewish General Hospital, Montreal, QC H3T 1E2, Canada.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2023 Dec 19; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 19.

Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control

Autor: Cahill, C.M, Morinville, A, Hoffert, C, O'Donnell, D, Beaudet, A

Publikováno v: In Pain 2003 101(1):199-208

Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer.

Autor: Gambaro K; Canadian National Centres of Excellence-Exactis Innovation, 5450 Cote-des-Neiges, Montreal, Quebec, H3T 1Y6, Canada.; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Marques M; Canadian National Centres of Excellence-Exactis Innovation, 5450 Cote-des-Neiges, Montreal, Quebec, H3T 1Y6, Canada.; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., McNamara S; Canadian National Centres of Excellence-Exactis Innovation, 5450 Cote-des-Neiges, Montreal, Quebec, H3T 1Y6, Canada., Couetoux du Tertre M; Canadian National Centres of Excellence-Exactis Innovation, 5450 Cote-des-Neiges, Montreal, Quebec, H3T 1Y6, Canada., Diaz Z; Canadian National Centres of Excellence-Exactis Innovation, 5450 Cote-des-Neiges, Montreal, Quebec, H3T 1Y6, Canada., Hoffert C; Canadian National Centres of Excellence-Exactis Innovation, 5450 Cote-des-Neiges, Montreal, Quebec, H3T 1Y6, Canada.; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Srivastava A; Canadian National Centres of Excellence-Exactis Innovation, 5450 Cote-des-Neiges, Montreal, Quebec, H3T 1Y6, Canada.; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Hébert S; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Samson B; Charles LeMoyne Hospital, 3120 Taschereau Blvd., Greenfield Park, Quebec, J4V 2H1, Canada., Lespérance B; Sacré-Coeur de Montréal, 5400 Boul. Gouin O, Montreal, Quebec, H4J 1C5, Canada., Ko YJ; Sunnybrook Health Science Centre, 2075 Bayview Ave., Toronto, Ontario, M4N 3M5, Canada., Dalfen R; St. Mary's Hospital, 3830 Lacombe, Montreal, Quebec, H3T 1M5, Canada., St-Hilaire E; Georges Dumont Hospital, 220 Avenue Universite, Moncton, New Brunswick, E1C 2Z3, Canada., Sideris L; Hôpital Maisonneuve Rosemont, 5415 Assumption Blvd, Montreal, Quebec, H1T 2M4, Canada., Couture F; Hôtel-Dieu de Quebec, 11 Cote du Palais, Montreal, Quebec, G1R 2J6, Canada., Burkes R; Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada., Harb M; Moncton Hospital, 135 Macbeath Ave, Moncton, New Brunswick, E1C 6Z8, Canada., Camlioglu E; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Gologan A; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Pelsser V; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Constantin A; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Greenwood CMT; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada.; Gerald Bronfman Department of Oncology, McGill University, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada.; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Tejpar S; Digestive Oncology Unit, Katholieke Universiteit Leuven, Oude Markt 13, Leuven, 3000, Belgium., Kavan P; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Kleinman CL; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada.; Department of Human Genetics, Lady Davis Research Institute, McGill University, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada., Batist G; McGill University-Segal Cancer Centre, Jewish General Hospital, 3755 Côte Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada.

Publikováno v: Clinical and translational medicine [Clin Transl Med] 2021 Apr; Vol. 11 (4), pp. e401.

Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.

Autor: Couëtoux du Tertre M; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada.; Exactis Innovation, Montréal, QC Canada., Marques M; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada.; Exactis Innovation, Montréal, QC Canada., McNamara S; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada.; Exactis Innovation, Montréal, QC Canada., Gambaro K; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada.; Exactis Innovation, Montréal, QC Canada., Hoffert C; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada.; Exactis Innovation, Montréal, QC Canada., Tremblay L; 3Institut universitaire de cardiologie et pneumologie de Québec, Université de Laval, Québec, QC Canada., Bouchard N; 4Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC Canada., Diaconescu R; 5Hopital Sacré-Cœur Montréal, Montréal, QC Canada., Blais N; 6Centre hospitalier universitaire de Montréal, Montréal, QC Canada., Couture C; 3Institut universitaire de cardiologie et pneumologie de Québec, Université de Laval, Québec, QC Canada., Pelsser V; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada., Wang H; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada., McIntosh L; 7Caprion, Montreal, QC Canada., Hindie V; 7Caprion, Montreal, QC Canada., Parent S; 7Caprion, Montreal, QC Canada., Cortes L; 7Caprion, Montreal, QC Canada., Breton YA; 7Caprion, Montreal, QC Canada., Pottiez G; 7Caprion, Montreal, QC Canada., Croteau P; 7Caprion, Montreal, QC Canada., Higenell V; Exactis Innovation, Montréal, QC Canada., Izzi L; Exactis Innovation, Montréal, QC Canada., Spatz A; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada., Cohen V; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada., Batist G; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada., Agulnik J; Segal Cancer Centre, Jewish General Hospital, McGill University, Jewish General Hospital, 3755, Chemin Cote Ste-Catherine, Montreal, QC H3T1E2 Canada.

Publikováno v: Clinical proteomics [Clin Proteomics] 2020 Feb 07; Vol. 17, pp. 5. Date of Electronic Publication: 2020 Feb 07 (Print Publication: 2020).

Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control

Autor: Cahill, MC, Morinville, A, Hoffert, C, O'Donnell, D, Beaudet, A

Publikováno v: Cahill, MC; Morinville, A; Hoffert, C; O'Donnell, D; & Beaudet, A. (2003). Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control. Pain, 101(1), 199-208. doi: 10.1016/S0304-3959(02)00333-0. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5c98997v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::b57451532afde62f26259019fd894da7
http://www.escholarship.org/uc/item/5c98997v